InvestorsHub Logo

EOT

Followers 114
Posts 12404
Boards Moderated 1
Alias Born 05/05/2014

EOT

Re: None

Tuesday, 10/08/2019 9:25:15 AM

Tuesday, October 08, 2019 9:25:15 AM

Post# of 113787
Those who can’t forget about the past could miss out on the biggest cancer news EVER.

Imo The plan is now clear.....
They completed the RS and then they dropped this Huge Bomb with this rectified patent...
THE MISSING INGREDIENT (new subject matter)


“The new patent (US Patent Application Number 20150353573) contains new subject matter “




For Immediate Release February 4, 2019
SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF Adva-27a ANTICANCER DRUG UNTIL 2033

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFMD”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer.

The new patent (US Patent Application Number 20150353573) contains new subject matter and extends the proprietary protection of Adva-27a until 2033. Sunshine Biopharma is the sole owner of all existing intellectual property rights and patents pertaining to Adva-27a, including US Patent Number 8,236,935 issued in 2012.

“We are very excited about this significant development for Adva-27a,” said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. “Allowance of the second Adva-27a patent application gives us 14 years of additional protection and is a validation of the unique and innovative aspects of our anticancer molecule,” he added.

Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. Tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are currently being planned to be conducted at the McGill University Hospital Centers in Montreal, Canada.

Direct Line: 514-814-0464 camille.sebaaly@sunshinebiopharma.com www.sunshinebiopharma.com





Forget about the past.. ...
IMO With the New Patent and sudden huge dilution I believe a BIG announcement is coming to begin clinical trials .....

“Clinical trials for Pancreatic Cancer indication are currently being planned to be conducted at the McGill University Hospital Centers”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SBFM News